Protocol Ledger

NCT05744687 · Phase II/III · RECRUITING

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Interventional Phase II/III clinical trial protocol NCT05744687 sponsored by Shanghai Pharmaceuticals Holding Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-24 Enrollment: 374 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05744687
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)374 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05744687
Protocol FieldVerified Registry Value
NCT IdentifierNCT05744687
Consolidated Lead SponsorShanghai Pharmaceuticals Holding Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment374 participants (ESTIMATED)
Registered Start Date2023-04-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI